Galapagos Nv (GLPG) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Galapagos Nv  (NASDAQ: GLPG)

Galapagos Nv's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Galapagos Nv in the fourth quarter 2025?
Galapagos Nv achieved a return on average equity (ROE) of 9.92 % in its fourth quarter 2025 a new company high.

ROE has advanced compared to 2.35% in the third quarter 2025, due to net income growth.

Within the Major Pharmaceutical Preparations industry 61 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 0 to 1466.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Equity Change 11.7 % 11.7 % 11.7 % 11.7 % -
Y / Y Net Income Change 333.15 % - - - -65.01 %
Net Income (TTM) in Millions 359 83 83 83 83
Return On Equity (TTM) 9.92 % 2.35 % 2.42 % 2.48 % 2.56 %
GLPG's Total Ranking # 1466 # 0 # # #
Equity (TTM) in Millions 3,624 3,624 3,624 3,624 3,245
Seq. Equity Change 0 % 0 % 0 % 11.7 % 0 %
Seq. Net Income Change - - - - -

Back to GLPG Management Effectiveness >> GLPG's 5 Years Annual ROE >> Compare GLPG ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 62
Sector # 164
Overall # 1466

Return On Equity Statistics
High Average Low
9.92 %
-0.25 %
-11.44 %
(Dec 31 2025)   (Dec 31 2020)





GLPG Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 3,624 3,245 3,131 2,829 2,961
Y / Y Equity Change 11.7 % 3.63 % 10.67 % -4.44 % -1.01 %
Net Income in Millions 359 83 237 -244 -116
Y / Y Net Income Change 333.15 % -65.01 % - - -
Return On Equity 9.92 % 2.56 % 7.57 % -8.63 % -3.91 %

Back to GLPG Management Effectiveness >> GLPG's 5 Years Annual ROE >> Compare GLPG ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 9.92 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
GLPG's' Return on Equity at Yahoo Finance
GLPG's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for GLPG's Competitors
Subscribers only: Roe for Galapagos Nv's Suppliers
Subscribers only: Return On Equity for GLPG's Customers




Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector ROE
Resmed Inc   25.18 %
Encompass Health Corporation  24.76 %
Prestige Consumer Healthcare Inc   24.66 %
Catalyst Pharmaceuticals Inc   24.32 %
Collegium Pharmaceutical Inc   24.11 %
Xoma Royalty Corporation  23.97 %
Chemed Corporation  23.92 %
Iradimed Corporation  23.83 %
Lifevantage Corp  23.04 %
Hims and Hers Health Inc   22.99 %
Vertex Pharmaceuticals Inc  22.70 %
Pacs Group Inc   22.54 %
Spero Therapeutics Inc   22.53 %
Iqvia Holdings Inc   22.05 %
Ge Healthcare Technologies Inc   21.90 %
Msa Safety Inc  21.82 %
Mimedx Group Inc   21.24 %
Universal Health Services Inc   21.19 %
Inspire Medical Systems inc   21.07 %
Astrazeneca Plc  21.00 %
Haemonetics Corporation  20.80 %
Sbc Medical Group Holdings Incorporated  20.79 %
Lantheus Holdings Inc   20.58 %
Electromed Inc   20.54 %
Teva Pharmaceutical Industries Limited  20.07 %
Harmony Biosciences Holdings inc   19.84 %
Pediatrix Medical Group Inc   19.58 %
United Therapeutics Corporation  19.30 %
Krystal Biotech Inc   18.69 %
Argenx Se  17.64 %

Date modified: 2026-07-07T11:24:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.